Velegraki Magdalini, Arna Despoina, Nikolaou Pinelopi, Psistakis Andreas, Fragaki Maria, Chlouverakis Gregorios, Vardas Emmanouil, Paspatis Gregorios
Department of Gastroenterology, Venizeleion General Hospital, Heraklion, Crete, Greece (Magdalini Velegraki, Despoina Arna, Pinelopi Nikolaou, Andreas Psistakis, Maria Fragaki, Emmanouil Vardas, Gregorios Paspatis).
Department of Social Medicine, Biostatistics Lab, School of Medicine, University of Crete, Heraklion, Crete, Greece (Gregorios Chlouverakis).
Ann Gastroenterol. 2024 Jan-Feb;37(1):89-94. doi: 10.20524/aog.2023.0855. Epub 2023 Dec 23.
Stone recurrence is a significant complication following endoscopic bile duct clearance. Endoscopic papillary large-balloon dilation (EPLBD) with biliary sphincterotomy (EBS) has shown satisfactory results in preventing recurrence of "large" common bile duct stones (CBDS). However, data on outcomes after EPLBD+EBS for CBDS ≤12 mm remain scarce. The present study prospectively evaluated the mid- and long-term efficacy of EPLBD+EBS for CBDS recurrence among this group of patients.
Consecutive patients with CBDS ranging from 8-12 mm, treated with EPLBD+EBS from June 2018 through June 2020, were prospectively followed-up for at least 36 months. CBDS recurrence was defined as recurrent stones confirmed by endoscopic retrograde cholangiopancreatography (ERCP) during the follow-up period.
Overall, 72 patients (mean age: 67 years, 52.8% male) were included, of whom 22 (30.5%) had multiple (≥3) CBDS, 23 (31.9%) had a history of cholecystectomy, 13 (18.1%) had a periampullary diverticulum and 22 (30.5%) had a previous EBS. The mean CBD diameter was 11.6±1 mm, while a tapered duct was noted in 7 (9.7%). Post-procedural bleeding and cholangitis occurred in 1 and 2 cases respectively. No cases of perforation and post-ERCP pancreatitis were observed. During a mean follow up of 46.4±6.2 months (range 37-60), no mid-term recurrence was observed, whereas CBDS recurred in 2/72 (2.7%) in the long term.
EPLBD+EBS in patients with CBDS ≤12 mm was associated with a very low rate of mid- and long-term CBDS recurrence. Our results need to be further investigated with randomized controlled trials.
结石复发是内镜下胆管清除术后的一种重要并发症。内镜乳头大球囊扩张术(EPLBD)联合胆管括约肌切开术(EBS)在预防“大”胆总管结石(CBDS)复发方面已显示出令人满意的效果。然而,关于EPLBD+EBS治疗直径≤12mm的CBDS后的结果数据仍然很少。本研究前瞻性评估了EPLBD+EBS对该组患者CBDS复发的中长期疗效。
对2018年6月至2020年6月期间接受EPLBD+EBS治疗的8-12mm CBDS连续患者进行前瞻性随访至少36个月。CBDS复发定义为随访期间经内镜逆行胰胆管造影(ERCP)证实的复发性结石。
总体纳入72例患者(平均年龄:67岁,男性占52.8%),其中22例(30.5%)有多发(≥3个)CBDS,23例(31.9%)有胆囊切除术史,13例(18.1%)有壶腹周围憩室,22例(30.5%)曾接受过EBS。CBD平均直径为11.6±1mm,7例(9.7%)可见胆管呈锥形。术后分别有1例和2例发生出血和胆管炎。未观察到穿孔和ERCP后胰腺炎病例。在平均46.4±6.2个月(范围37-60个月)的随访期间,未观察到中期复发,而长期有2/72(2.7%)发生CBDS复发。
EPLBD+EBS治疗直径≤12mm的CBDS患者,中长期CBDS复发率非常低。我们的结果需要通过随机对照试验进一步研究。